Kite announced the preparation of car-t cells
On July 12, 2017 / d MaiKe eMedClub / - in the face of the listed at the end of the time periods, Kite has been committed to strengthen its production process, the CAR - T cells in the latest issue of the experiment, make team to give the patients' cell cycle shorten nearly six days.
At present, Kite company related department says it has veins to vein (cell in vitro amplification to treatment) shorter time to about 17 days, and they also think that still can have 2-3 days can shorten the space.
In July 2016, the Kite to enable the company is located in California, 43500 - square - foot CAR - T preparation plant, the plant is close to Los Angeles international airport, so construction in its neighborhood factories for CAR - fast delivery is an excellent choice of T cells.
This enables Kite company to guarantee the manufacturing time of car-t, which can guarantee the preparation of cart-t cells every year.
CAR - T therapy as a "live", its treatment process including: taking the patient's immune cells, under the condition of low temperature air to California CAR - T cell preparation plant, the immune cells in the factory after 6 to 8 days in vitro genetic modification, genetically engineered T cells after the CAR back to the patient's body, can be specific to identify and kill tumor cells, and the CAR - T cells will not harm the body's normal cells.
So time is definitely one of the most critical aspects of car-t cell therapy.
It is worth noting that the Kite company cells extracted from patients, to the CAR - T cells feed back into the patient's body, a process that takes about 16 to 18 days (may also be shortened to 14 days) of the time, compared to novartis's 22-29 days and Juno, 24 days of preparation time, Kite is undoubtedly the fastest CAR - T cells product preparation.
Kite kte-c19 milestone event
In December 2015.
Kite Pharma announced that its car-t candidate, kte-c19, received a breakthrough treatment from the FDA for r/r DLBCL.
In March 2017,
Kite Pharma announced the application of the bio-product permit application (BLA) of its car-t candidate drug kte-c19 (BLA).
In May 2017,
Kite Pharma has announced that the us FDA has issued a priority review of its first biology-approved biological preparations for its car-t therapy axicabtageneciloleucel, and is scheduled to be awarded on 29 November this year.
The priority qualification also marks a further step towards the promise of the first car-t therapy for refractory invasive non-hodgkin's lymphoma.